Everest Medicines (China) Co.,Ltd. | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration	Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder	Not yet recruiting	Phase 2	2026-09-10		NCT07798375
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, focal segmental glomerulosclerosis, glomerulonephritis, immune system disorder, kidney disorder, minimal change disease, nephritis, nephrosis, urinary system disorder	Recruiting	Phase 2	2026-08-05		NCT07614477
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors	Advanced or Recurrent Solid Tumors	Recruiting	Phase 1	2026-06-22		NCT06541639
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases	Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Skin and Connective Tissue Diseases, autoimmune disease, autoimmune disorder of the nervous system, connective tissue disorder, diffuse scleroderma, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, scleroderma, skin disorder, systemic lupus erythematosus, systemic sclerosis	Recruiting	Not applicable	2026-03-13		NCT07470151